Letters DPP-4 inhibitors for type 2 diabetes

Report was overpositive about their benefits

BMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2917 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2917
  1. Rafael S Scheffel, endocrinologist,
  2. Beatriz D Schaan, postgraduate student
  1. 1Hospital de Clínicas de Porto Alegre, Serviço de Medicina Interna, Porto Alegre, RS, Brazil

Although Karagiannis and colleagues’ study has methodological strengths worth citing, we disagree with some of the conclusions.

In the evaluation of the prespecified primary endpoint (difference in glycated haemoglobin (HbA1c); fig 2), the performance of the dipeptidyl peptidase-4 (DPP-4) inhibitors was far below that of the drugs used as active comparators …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe